Double-blind trial of feprazone and phenylbutazone in acute gout

A double-blind trial was carried out in 24 patients with acute gout to compare the efficacy and tolerance of feprazone, a non-steroidal anti-inflammatory drug, with that of phenylbutazone. Patients received 800 mg of either drug daily for 2 days and then 600 mg daily for up to 8 days. The results of...

Full description

Saved in:
Bibliographic Details
Published inCurrent medical research and opinion Vol. 6; no. 7; p. 445
Main Authors Reardon, J A, Stockman, A, Darlington, L G, Scott, J T
Format Journal Article
LanguageEnglish
Published England 1980
Subjects
Acute Disease
Adult
Aged
Clinical Trials as Topic
Double-Blind Method
Female
Feprazone - therapeutic use
Gout - drug therapy
Humans
Male
Middle Aged
Phenylbutazone - analogs & derivatives
Phenylbutazone - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:A double-blind trial was carried out in 24 patients with acute gout to compare the efficacy and tolerance of feprazone, a non-steroidal anti-inflammatory drug, with that of phenylbutazone. Patients received 800 mg of either drug daily for 2 days and then 600 mg daily for up to 8 days. The results of patient assessment showed there was no significant difference between the two groups in time taken either to significant improvement or to final resolution of the gout attack. No side-effects were reported with either drug.
ISSN:0300-7995
DOI:10.1185/03007998009109465